Review Article

New Insights into the Epigenetics of Hepatocellular Carcinoma

Braira Wahid,1 Amjad Ali,1 Shazia Rafique,1 and Muhammad Idrees1,2

1Centre for Applied Molecular Biology, 87 West Canal Bank Road Thokar Niaz Baig, University of the Punjab, Lahore, Pakistan
2Hazara University, Mansehra, Pakistan

Correspondence should be addressed to Amjad Ali; amjad.camb@pu.edu.pk

Received 26 August 2016; Accepted 17 January 2017; Published 19 March 2017

Academic Editor: Mario Scartozzi

Copyright © 2017 Braira Wahid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatocellular Carcinoma (HCC) is one of the most predominant malignancies with high fatality rate. This deadly cancer is rising at an alarming rate because it is quite resistant to radio- and chemotherapy. Different epigenetic mechanisms such as histone modifications, DNA methylation, chromatin remodeling, and expression of noncoding RNAs drive the cell proliferation, invasion, metastasis, initiation, progression, and development of HCC. These epigenetic alterations because of potential reversibility open way towards the development of biomarkers and therapeutics. The contribution of these epigenetic changes to HCC development has not been thoroughly explored yet. Further research on HCC epigenetics is necessary to better understand novel molecular-targeted HCC treatment and prevention. This review highlights latest research progress and current updates regarding epigenetics of HCC, biomarker discovery, and future preventive and therapeutic strategies to combat the increasing risk of HCC.

1. Introduction

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world that causes 250,000 to 1 million deaths annually [1]. This alarming incidence is attributed to several different genetic and epigenetic alterations. HBV and HCV infections, smoking, alcohol, dietary exposure to aflatoxins, diabetes, and obesity are the other risk factors of HCC [2]. Epigenetic changes that contribute to HCC metastasis, invasion, and dissemination encompass noncoding RNAs regulation, DNA methylation, and histone modification. All these changes are associated with initiation and progression of HCC [3].

2. Epigenetic Changes in HCC

Epigenetics refers to heritable states of gene expression without alteration to the DNA sequence itself. Epigenetic changes such as DNA hypermethylation or hypomethylation, dysregulation of histone modification patterns, chromatin remodeling, and aberrant expression of micro-RNAs (miRNAs) and long noncoding RNAs (lncRNAs) are associated with HCC [4]. Different epigenetic mechanisms that drive cell proliferation, metastasis, progression, and development of HCC are discussed below.

3. DNA Methylation

DNA methylation, specifically methylation of cytosine at 5th carbon, is a well characterized epigenetic mechanism of gene regulation that occurs in mammals at promoter-rich region of gene that is, cytosine-phosphate-guanine (CpG) (Figure 1).

CpG dinucleotides occur throughout human genome in nonuniform manner with the frequency of about one per eighty nucleotides [5]. Approximately 1 to 2% of human genome is referred to as CpG islands or CpG-rich regions containing hundred to several thousand base pairs and exists in proximity to different gene promoter regions [6]. Nearly 70% of human genes harbor CpG islands at 5′ region that consist of promoter as well as transcription sites [7].

In HCC and other wide range of tumors, specific promoter hypermethylation and global hypomethylation have been associated with inactivation of tumor-suppressor genes (TSGs) and genomic instability, respectively. Silencing of tumor-related genes and tumor-suppressor genes such as SOCS1, hMLHI, and RASSFIA is achieved by hypermethylation of CpG islands in promoter sequences that down-regulates mRNA transcript expression. Epigenetic silenced genes play an important role in molecular pathways of carcinogenesis such as cell adhesion or DNA repair, apoptosis, and cell cycle regulation [8]. Set of proteins known as
Figure 1: CpG methylation. (a) DNA methylation is catalyzed by three methyl transferase genes (DNMT1, DNMT3a, and DNMT3b) that add methyl group (CH₃) at 5th carbon position of pyrimidine ring of cytosine. S-adenosyl methionine (SAM-CH₃) acts as a methyl donor. (b) Cytosine to cytosine sulfonate: sulfonation of cytosine causes C to T transition followed by deamination. Cytosine sulfonate to uracil sulfonate: conversion of cytosine sulfonate to uracil sulfonate leads to alkali desulfonation. Uracil sulfonate is converted into uracil. PCR distinguishes methylated CpG from unmethylated CpG because methylated cytosine resists this chemical treatment [124, 125].

Ten-eleven translocation (Tet1–3) demethylates methylcytosine via hydroxymethylcytosine (hmC) [9]. It has been reported that level of hmC reduces in various types of cancers [10]. However, the mechanism of this downregulation is still to be determined [11].

Different DNA methylome patterns as compared to adjacent normal tissues have been observed in independent genome-wide methylation profiling studies. HCC and non-HCC surrounding liver tissues can be distinguished easily because aberrant DNA hypermethylation is specific to the cancerous tissues. Likewise, a set of hypermethylated gene promoters, for example, FZD7, CDKN2A, RASSF1A, and APC, were able to distinguish nontumor liver tissues from HCC tumors. Another study recruited 27 patients and revealed the significant level of DNA methylation of NFATC1, GSTP1, CDKN2A, and BMP4 genes in HCC tissues [12]. Lambert et al. have recently analyzed the methylation status of set of imprinted genes in HCC and found that 15q11-13 imprinting control region that includes maternally imprinted GABRA5 gene was significantly hypomethylated in tumors compared to their surrounding tissues. The study suggested that imprinted gene methylation acts as a potential marker of environmental exposures [13].

Poor tumor differentiation is attributed to promoter methylation of DNMT1 [14, 15]. S100A8 can be used as prognostic and diagnostic biomarker because of its overexpression...
observed in MHCC-97H and Huh-7 cell lines [16]. Likewise, HK2 promoter CpG island (HK2-CGI) represents prognostic biomarker of HCC because hypermethylation of HK2-CGI induces HK2-CGI methylation phenotype (HK2-CIMP) [17] (Table 1).

Other frequently methylated genes in HCC include RIZI (45.2%), CDKN2A (69.7%), SCARNA5 (30%), EEFEMP1 (50%), TIP30 (47%), WIFI, FBXN1 (50%), DLEC1 (70.6%), FBPI (80%), ITGA4 (23%), KLK10 (94%), LIFR (47.9%), MTIG (60.4%), HHIIP (53.6%), HINTI (55%), SYK (12%), and TAT (54%) [18,19].

Bead array analysis of 1505 CpG sites in thirty HBV- or HCV-associated HCC infected patients revealed the correlation of specific methylation signatures with tumor progression stage in HCC tumor patients. Hypermethylation of SYK (spleen tyrosine kinase) or CHFR (checkpoint with fork-head associated and ring finger) occurs specifically in advanced stages of HCC, whereas abnormal DNA methylation of p15, GAAD45a, SFRP1, DOK1, CHRNA3, GSTP1, CRABP1, p16, and RASSF1A occurs at all stages of HCC [20–23]. HBV-encoded protein (HBx) affects the methylation and expression by directly interacting with DNMT (DNA-methyltransferase). The prevalence of TSGs methylation, for example, p15, APC, STAT1, GADD45b, and SOCS-1, has been observed to be higher in HCV-positive HCC compared to HCV-negative HCC [24, 25]. Hernandez-Vargas et al. revealed that panel of hypermethylated genes, for example, DCC, CSPG2, and NAT2, was specific to HBV-related HCC [26, 27] and methylation of constitutive androstane receptor (CAR) suppresses CYP2C19 in HBV-associated HCC patients [28]. According to Shih et al. methylation of PAX6 frequently occurs in HCV-associated HCC tissues (61.3%) compared to HBV positive (22.1%) and double negative HCC tissues (33.3%) [29].

A genome-wide methylation study including 69% HBV-associated HCC patients demonstrated that PAX4, WFD3C6, SCGB1D1, ATX3, and CCL20 were top five hypomethylated genes, whereas CDKN2A, SPY1Z, ZFPA1, BMP4, and DAB2IP were found to be top five hypermethylated genes [30]. Nishida et al. demonstrated that DNA methylation is an important mechanism in silencing the set of 8 TSGs that predict HCV progression to HCC [31]. NEFH and SMPD3 have been proved as potent tumor-suppressor genes in HCC [32]. Based on the above findings it can be concluded that early diagnosis and prognosis of HCC can be achieved by methylation profiling because of close association of aberrant gene methylation with clinical outcome and HCC disease stage. However, specific gene methylation signatures must be validated [26]. Recent study has suggested that DNA methylation of miRNA genes may provide a promising strategy for alternative adjuvant therapy in HCC [33].

4. Histone Modification

Histone modifications also known as “histone code” have direct impact on gene expression and chromatin structure. These epigenetic changes are of paramount importance in gene silencing during tumorigenesis [107]. Modifications such as ubiquitination, phosphorylation, methylation, and acetylation that occur at N-terminal tails of nucleosomal histones work together with other epigenetic mechanisms to regulate gene activities and cellular processes. Orderly and coordinated activities of diverse histone modifications regulate cellular processes, for example, DNA repair, DNA replication, and gene transcription. It has been reported that control of chromatin-based processes (responsible for cancer development and oncogenic transformation) is deregulated by functional changes in protein complexes and histone-modifying molecules [108].

DNA methylation is closely associated with histone modification because inhibitors reverse the histone modification changes on H3-K4 and H3-K9 codes [109, 110]. Another distinct histone modification involved in Polycomb-based silencing and X-chromosome inactivation in women is H3K27 trimethylation that is one of the candidates for a silencing mechanism for tumor-suppressor genes [111]. Overexpression of enhancer of zeste homolog 2 (EZH2) is associated with different types of cancer and it has been studied that EZH2 catalyzes histone H3-K27 trimer (H112). Histone methyltransferases (HMT), SUV39H1 and G9a, mediate the histone H3-K9 trimethylation and dimethylation (H3-K9 dime), respectively [113]. H3K9 methylation is associated with silencing of several tumor-suppressor genes [114]. Significant decrease in histone H2A ubiquitination was noticed in HCC [115].

Researchers have reported several histone modifications that are associated with HCC and alter normal cellular processes; for example, Magerl et al. found negligible expression of dimethylation of histone H3 at lysine 4 (H3K4dim) in HCC [116] whereas, according to Shon et al., Ptt1 (a GNAT family acetyltransferase) is downregulated in HCC and it is overexpressed in healthy liver [117]. Somatic mutation that induced inactivation of MLL1–5 enzymes responsible for H3K4Me has been reported in 1–6% of HCC [118]. Integration of HBV into MLL2 and MLL4 gene loci has also been identified in many cases of HCC [119]. In contrast to this, elevated H3K4me3 is associated with mutations in SMYD3 methyltransferase resulting in poor prognosis specifically during the initial stages of HCC [120]. Likewise, upregulation of SETDB1, another histone methyltransferase for H3K9, was observed in HCC. Overexpression of SETDB1 that is closely associated with metastasis and cancer progression actually is triggered by downregulation of miR-29 and gain of chromosome 1q21 [121, 122]. About 2.6% of cancer patients experience mutations in SETDB2 gene [118, 123].

Histone deacetylases (HDACs) are the enzymes that play an important role in regulation of gene expression by removing acetyl group from histones that make the DNA more compact leading to gene silencing. About 18 HDACs are known with activity not limited to just histones because it has been reported that HDACs remove acetyl-lysine on diverse nonhistone proteins like NFkB, transcription factors p53, and many others [128].

Accumulating evidence suggests the correlation of individual HDACs overexpression with poor prognosis in different types of cancer including HCC [129]. Overexpression of HDAC3 was correlated with early recurrence of HCC after surgery and advance tumor stage. Tumor-suppressor
Table 1: Aberrant DNA methylation markers for HCC.

| Gene and its location | Function                  | Methylation frequency% in adjacent normal tissue | Methylation frequency% in HCC | Ref.    |
|-----------------------|---------------------------|-------------------------------------------------|-----------------------------|---------|
| WT1                   | Urogenital development    | 0                                               | 54                          | [34]    |
| 11p13                 |                           |                                                 |                             |         |
| TIMP3                 | Cell adhesion             | 0                                               | 13                          | [35]    |
| 22q12.3               |                           |                                                 |                             |         |
| SOCS-1                | Cytokine inhibitor        | 0–7                                             | 43–65                       | [36]    |
| 16p13.13              |                           |                                                 |                             |         |
| SEMA3B                | Apoptosis                 | —                                               | 83                          | [37]    |
| 3p21.3                |                           |                                                 |                             |         |
| RB                    | Chromatin structure       | 0                                               | 32                          | [34]    |
| 13q14.2               |                           |                                                 |                             |         |
| RASSF1A                | Apoptosis                 | 0                                               | 59–75                       | [35, 37]|
| 3p21.3                |                           |                                                 |                             |         |
| Rab-R-Beta            | Retinoic acid signaling   | 7                                               | 12                          | [36]    |
| 3p24.2                |                           |                                                 |                             |         |
| P73                   | Tumor suppressor          | 0                                               | 6                           | [36]    |
| 1p36.32               |                           |                                                 |                             |         |
| P53                   | Tumor suppressor          | 0                                               | 14                          | [34]    |
| 17p13.1               |                           |                                                 |                             |         |
| P300                   | Growth/cell division      | 0                                               | 65                          | [34]    |
| 22q13.2               |                           |                                                 |                             |         |
| P27                   | CDK inhibitor             | 0                                               | 48                          | [34]    |
| 12p13.1               |                           |                                                 |                             |         |
| P21                   | CDK inhibitor             | 10                                              | 63                          | [34]    |
| 6p21.2                |                           |                                                 |                             |         |
| P16^{INK4a}           | CDK inhibitor             | 0–10                                            | 16–83                       | [35, 36]|
| 9q21.3                |                           |                                                 |                             |         |
| P15                   | CDK inhibitor             | 0                                               | 42–47                       | [36]    |
| 18q12.2               |                           |                                                 |                             |         |
| P14                   | CDK inhibitor             | 0                                               | 6                           | [36]    |
| 11q13.1               |                           |                                                 |                             |         |
| hMLH1                 | Mismatch repair           | 0                                               | 0                           | [35]    |
| 3p21.3                |                           |                                                 |                             |         |
| GSTP1                 | Glutathione synthesis     | 0–7                                             | 41–76                       | [35, 36]|
| 11q13                 |                           |                                                 |                             |         |
| E-Cadherin            | Cell adhesion             | 7                                               | 33–67                       | [34–36] |
| 16q22.1               |                           |                                                 |                             |         |
| E2F-1                 | Transcription factor      | 0                                               | 70                          | [34]    |
| 20q11.22              |                           |                                                 |                             |         |
| DAPK1                 | Apoptosis                 | 0                                               | 10                          | [35]    |
| 9q21.33               |                           |                                                 |                             |         |
| CPS1                  | Urea cycling              | 0                                               | 80                          | [38]    |
| 2q34.6                |                           |                                                 |                             |         |
| COX2                  | Prostaglandin synthesis   | 0                                               | 35–50                       | [35]    |
| 1q31.1                |                           |                                                 |                             |         |
role of HDACs has also been noticed as overt HCC that occurred as a result of liver-specific knockdown of HDAC3 [130]. Specifically, persistent inactivation of SMRT, NCOR, or HDAC3 may lead to cancer development and DNA damage by increasing the histone acetylation during S phase [131]. HDACs may act as tumor suppressors and therapeutic targets in developing tumors and advanced cancer, respectively [132]. Inhibition of HDAC may disturb a drug design due to disruption of diverse pathways.

Some histone modifications also act as signature for risk factor exposures; for example, protein arginine methyltransferase 1 (PRMT1) catalyzes histone H4 methylation on arginine 3 and dephosphorylates damage-induced phosphorylation of H2AX (g-H2AX) to repair DNA. In case of HCV infection, Protein Phosphatase 2A (PP2Ac) is overly expressed and inhibits the activity of PRMT1 by binding to it. Overexpression of this phosphatase is considered an important event of viral hepatitis associated hepatocarcinogenesis. Compromised histone H2AX phosphorylation and histone H4 acetylation/methylation occur because of PP2Ac overexpression in HCV-associated HCCs leading to significant changes in gene expression for hepatocarcinogenesis and inhibition of DNA damage repair. Overexpression of this phosphatase is considered a critical early event in hepatocarcinogenesis in the context of chronic viral hepatitis [24, 133].

The direct interaction of HBx with histone acetyltransferase complex CBP/P300 supports the transcription transactivation property of an oncogenic transcription factor HBV-encoded HBx protein that affects the expression of different genes involved in apoptosis or cell cycle control. Recruitment of CBP/P300 complex that is mediated by HBx promotes transactivation and leads to acetylated (active) state of the target cellular genes [117, 134, 135]. Downregulation of CYP2E1 expression in response to deregulated histone modification which resulted in decline in apoptotic potential has been observed in alcohol-associated HCCs [136, 137]. Recent studies suggest that HCC progression can be repressed by inhibition of O-GlcNAcylation [138]. Epigenetic silencing of JMJD5 (jumonji C domain-containing protein 5), another tumor-suppressor gene in HCC pathogenesis, downregulates Cdkn1a transcription to promote HCC cell proliferation [139].

5. Chromatin Remodeling

Another important epigenetic mechanism that plays an important role in control of gene expression, differentiation, DNA repair, and proliferation is chromatin remodeling (Figure 2).

Nucleosomal restructuring by ATP-dependent chromatin remodeling complexes and enzymatic covalent histone modifications are the principal mechanisms involved in chromatin remodeling. Accumulating evidence in recent years has demonstrated that these complexes perform tumor-suppressor roles because of association of different malignancies with inactivated mutations [140]. Recent study based on SWI/SNF chromatin remodeling complex revealed that expression of brahma (BRM) was markedly decreased in HCC samples [141]. ARIDIA, ARIDIB, and ARID2 components that belong to SWI/SNF-related chromatin remodeling complexes are mutated at frequency of 16.8%, 6.7%, and 5.6%, respectively [142]. ARIDIA, ARIDIB, and ARID2 mutations are significantly observed in alcohol-associated HCC and HCV-related HCC, respectively [143]. Mutations in other components of SWI/SNF chromatin remodeling complex such as SMARCC2, SMARCC1, SMARCB1, SMARCA4, and SMARCA2 have also been commonly reported in HCCs. SMARCA2 mutations occur at frequency of 2.6% in alcohol-associated HCC [118]. Chromatin remodeler CHD1L that promotes HCC metastasis and progression may act as therapeutic target to control HCC [144]. The analysis of whole exome sequencing of 24 HCCs revealed that chromatin regulators are the third most frequently mutated genes [142].

6. Noncoding RNAs

Different human cancers are associated with noncoding RNAs based epigenetic mechanism of regulation of gene expression (Figure 3).

Noncoding RNAs are further categorized into two main types based on length: small/short noncoding RNAs that are <200 nucleotides including endogenous siRNAs, snRNAs, piRNAs, and miRNAs and long noncoding RNAs with length >200 nucleotides [145, 146]. Different functions of miRNA are described in Table 2.

Significant decrease in miRNA-129-2 with associated inhibition of HMGB1 (high mobility group box 1) has been observed in HCC [51]. miRNA22 that regulates Wnt1, igfIR, SRF, ADAM10, and cyclin G1 to play an active role in cell cycle progression is downregulated in HCC [44]. miRNA-125b and miRNA-26 induce cell-cycle arrest in HCC by targeting oncogenic LIN28B and cyclin D2/cyclin E2, respectively [43, 50]. Overexpression of miRNA-96 is observed in HBV-related HCC. In HCC cell lines, miRNA-101 targets VEGF-C resulting in the suppression of invasion [147]. miRNA-21 has been found upregulated in HCC and its degradation
BioMedResearchInternational

Figure 2: Emerging signaling pathways in HCC: chromatin remodeling: restricting transcriptional and DNA condensation occurs as a result of histone deacetylation catalyzed by HDACs in nucleosome. In contrast, transcriptional activation also occurs using chromatin remodeling complexes by allowing access to transcription machinery via nucleosome restructuring. Notch signaling: NOTCH receptor is cleaved photolytically when protein ligand binds to its extracellular domain. This binding releases its intracellular domain (NOTCH-ICD) that enters into nucleus to modify target gene expression (such as SOX9, HEY, and HES). Hedgehog (Hh) signaling: nuclear translocation of the transcription factor (TF) GLI occurs as a result of PTCH inhibitory effect on SMO and this event takes place in the presence of Hh signaling. Hippo signaling: kinase complexes Lats1/2-Mob1 and MST1/2-SVA1 are activated with phosphorylation of the transcription factor YAP resulting in prevention of its nuclear translocation. This event involves the use of upstream regulators of hippo pathway (i.e., FDM6, NF2, and FAT). Microbiota and lymphotoxins: NF-κβ signaling activates and produces proinflammatory molecules such as TNF-α and cytokines due to recognition of microbial ligands (LPS/PAMPs) by TLRs (e.g., TLR4) on the hepatic stellate cells [126].

can be used as target in therapeutics [148]. Likewise, recent study has demonstrated the tumor-suppressor activity of miRNA-214 by inhibiting CDK6, CDK3, and E2F2 [149]. In addition to inhibition of cell proliferation of HCC by miRNA-449a, lentivirus mediated overexpression of miRNA-199a, miRNA-133b, and miRNA-185 has also been reported [53, 59, 150, 151]. Oncogenic miRNA-221 and miRNA-1180 target cell cycle inhibitors (CDKNIC/p57, CDKNIB/p27) and repress TNIP2 expression, respectively, resulting in increased proliferation of HCC cells [39, 152]. Likewise, cell proliferation is suppressed in HCC due to let-7a and let-7g that regulates the oncogenic STAT3 and cMyc, respectively [42].
miRNA-135a targets fork-head box O1 and miRNA-155-3p suppresses FBXW7 leading to an increased invasion and migration in HCC [56, 153]. miRNA-186 targets Yes-associated protein 1 and acts as a potential therapeutic target in treating HCC [48].

Long noncoding RNAs also play an important role in different types of cancers including HCC. Scaffold, signal, guide, and decoy are the molecular mechanisms of IncRNAs [154, 155]. The most widely studied IncRNAs are described in Table 3.

Potential utilization of noncoding RNAs as novel candidates in treatment, detection, diagnosis, and prognosis of HCC are promising. During the last decade, accumulating evidence suggests the use of noncoding RNAs as potential therapeutic targets for HCC. However, pathological and biological aspects as well as molecular mechanism of noncoding RNAs in HCC are an emerging area of science that needs more research to develop potential therapeutic intervention and treatment against HCC.

7. Epigenetic Biomarkers of HCC

Epigenetic alterations such as DNA hypermethylation, DNA hypomethylation, and noncoding RNAs or histone modifications may serve as diagnostic and prognostic biomarkers of HCC.

Overexpression of histone phosphorylation proteins such as ARK1 and ARK2 and histone-modifying genes, such as histone methyltransferases G9a, EZH2, and SUV39H2, in HCC tissues predicts tissue invasion and poor prognosis [130, 156].

DNA methylation acts as potential biomarker of HCC because of higher frequency of aberrant methylation found in HCC tissues that can help a clinician or researcher to distinguish healthy liver from cirrhotic liver or liver of HCC patient [157]. Likewise, deregulated expression level of several noncoding RNAs can be used for diagnosis and prognosis of disease. Downregulation of miR-122 is associated with poor prognosis of HCC [158]. Studies showed decreased
expression of miR199a/b-3pis and increased expression of miR-21 in HCC tissues [159]. Deregulation of long noncoding RNA has also been reported in HCC tissues. Upregulation of HOTTIP and HOXAIR in HCC tissues has been associated with poor patient survival, tumor progression, and metastasis [74]. Recently, researchers predicted HCC with 100% specificity and 95.6% sensitivity based on DNA methylation level approach in preneoplastic liver tissue [160].

All these findings are encouraging to develop an epigenetic-based biomarker; however, more research regarding specificity, sensitivity, and reproducibility is needed to make the usability of methylated DNA, modified histones, and noncoding RNAs as novel and reliable biomarkers.

8. Nutritional Epigenetics

Occurrence of HCC can be reduced and the development of HCC can be delayed because of epigenetic mechanisms deregulated by nonnutrient dietary bioactive components and several different nutrients. Liver carcinogenesis is under the influence of chemopreventive potential of epigenetic food components such as dietary methyl-group donors, that is, sulforaphane, sodium butyrate, curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG). Food-based deregulation of epigenome contributes towards HCC-related angiogenesis, oxidative stress, apoptosis, inflammation, and cell proliferation.

Several in vivo and in vitro preclinical models of HCC have demonstrated the antihepatocarcinogenic effects of polyphenolic compound curcumin that demethylates DNA and expresses DNMTs to reactivate abnormally silenced cancer related genes [161]. Green tea beverages are enriched with EGCG that have enough potential to inhibit progression and development of HCC via DNA demethylation of abnormally hypermethylated tumor-suppressor genes [162]. Two coffee polyphenols, that is, chlorogenic acid and caffeic acid, inhibited liver carcinogenesis in rat and the inhibition of human DNMT1-mediated enzymatic DNA methylation reaction has also been reported [163, 164].

Abundant HDAC inhibitors are of natural origin and present in different plants such as broccoli (sulforaphane), grapes (resveratrol), blueberries (piceatannol), and garlic

| miRNA | Function of miRNA | Gene target involved | Reference |
|-------|-------------------|----------------------|-----------|
| miRNA-221 | Oncogenic | DDIT4, CDKN1C/p57, CDKN1B/p27 | [39] |
| miRNA-125b | Tumor suppressor | LIN28B | [40] |
| miRNA-214 | Tumor suppressor | c-Myc, TCF-1, Cyclin D1 | [41] |
| let-7 family | Tumor suppressor | c-Myc, STAT3 | [42] |
| miRNA-26 | Tumor suppressor | MMP2, cyclin D1, Mcl-1, Bcl-2 | [43] |
| miRNA-122 | Tumor suppressor | ADAM10, IgFIR, SRF, Cyclin G1, Wnt1, AKT3, Bcl-w | [44, 45] |
| miRNA-96 | Oncogenic | ephrinA5 | [46] |
| miRNA-101 | Tumor suppressor | Mcl-1 | [47] |
| miRNA-186 | Tumor suppressor | Yes-associated protein 1 | [48] |
| miRNA-29 | Tumor suppressor | Mcl-2, Bcl-2 | [49] |
| miRNA-125b | Tumor suppressor | ILL-6R, Bcl-w, Mcl-1, Bcl-2 | [50] |
| miRNA-129-2 | Tumor suppressor | High mobility group box 1 | [51] |
| miRNA-193a-3p | Oncogenic | SRSF2 | [52] |
| miRNA-133b | Tumor suppressor | SIRT1 | [53] |
| miRNA-199a-3p | Tumor suppressor | c-Met, mTOR | [54] |
| miRNA-199a-5p | Tumor suppressor | ATG7 | [55] |
| miRNA-155-3p | Oncogenic | FBXW7 | [56] |
| miRNA-222 | Oncogenic | PPP2R2A, p27 | [57] |
| miRNA-21 | Oncogenic | PTEN, kinase 3 | [58] |
| miRNA-449a | Tumor suppressor | ADAM10 | [59] |
| miRNA-139 | Tumor suppressor | ROCK2, Rho Kinase 2 | [60] |
| miRNA-125b | Tumor suppressor | LIN28B, PDZ binding motif, Sirtuin 7 | [40, 50, 60] |
| miRNA-182 | Oncogenic | ephrinA5 | [46] |
| miRNA-125a | Tumor suppressor | VEGF-A, MMP11 | [61] |
| miRNA-1180 | Increase apoptotic resistance to HCC | Through activation of NF-κB pathway | [62] |
| miRNA-200 family | Tumor suppressor | ZEB2, ZEB1 | [63] |
| miRNA-212 | Tumor suppressor | FOXA1 | [64, 65] |
| miRNA-497 | Tumor suppressor | YAP1 | [66] |
| miRNA-519d | Metastasis | PTEN | [67] |
| miRNA-106b | Apoptosis | Bim | [68] |
Table 3: The potential roles of widely studied HCC-related lncRNAs.

| lncRNA | Potential role in HCC | Ref. |
|--------|-----------------------|------|
| HOTAIR | Overexpression of HOTAIR is associated with progression of HCC via activation of Wnt/β-catenin signaling pathway, and ATG3 and ATG7 that ultimately activate autophagy and promote HCC cell proliferation. | [69, 70] |
| CCAT1  | CCAT1 functions as let-7 sponge and increases HCC progression. | [71] |
| HULC   | HULC increases the metastasis and tumorigenesis of HCC through miR-200a-3p/ZEB1 signaling pathway. Low expression of H19 decreases HCC progression and metastasis via upregulation of miR-200 family. | [72] |
| H19    | H19 is negatively regulated by miR-125b. | [73] |
| HOTTIP | HOTTIP overexpression is associated with metastasis in HCC patients. This lncRNA is negatively regulated by miR-125b. | [74, 75] |
| BANCR  | BANCR is considered as an important contributor of progression and initiation of HCC and therefore can be used as biomarker. | [76] |
| MALAT1 | MALAT1 is associated with tumor progression because of its upregulation in HCC cell lines. | [77] |
| HEIH   | HEIH is oncogenic in nature and promotes tumor progression. | [78] |
| PTENP1 | PTENP1 represses tumorigenic properties of HCC cells. | [79] |
| SNHG20 | SNHG20 is upregulated in HCC and may serve as prognostic biomarker of HCC. | [80] |
| MEG3   | MEG3 is associated with pathogenesis of HCC malignancy. Uptregulation of MEG3 is associated with progression of HCC. | [81] |
| TUC338 | TUC338 and TUC339 modulates cell growth and increases liver cirrhosis. LINC-ROR acts as mediator of chemotherapeutic response and increases chemosensitivity in HCC because HCC is highly resistant to chemotherapy. It also promotes cell survival during hypoxia. | [82, 83] |
| LINC-ROR | LINC-ROR confirms overall-survival and recurrence-free survival. IncRNA-ATB signaling acts as a mediator of TGF-β signal that increases metastasis in HCC. | [84, 85] |
| MVIH   | MVIH is important in tumor suppression. Downregulation of MVIH inhibits HCC metastasis by targeting vimentin. | [86] |
| IncRNA-ATB | IncRNA-ATB signaling acts as a mediator of TGF-β signaling that increases metastasis in HCC. | [87] |
| TUG1   | Uptregulation of TUG1 in HCC and increasing apoptosis and cell growth by epigenetic silencing of KLF2. URHC expression is increased in HCC tissues. It regulates apoptosis and cell proliferation via downregulation of ZAK. Binds to miR-374a and MCM2 and inhibits metastasis and proliferation in HCC. | [88, 89] |
| URHC   | IncRNA-LET is associated with reduction in HCC metastasis and invasion. IncRNA-Dreh is important in tumor suppression. Downregulation of Dreh inhibits HCC metastasis by targeting vimentin. | [79, 81] |
| FTX    | FTX binds to miR-374a and MCM2 and inhibits metastasis and proliferation in HCC. | [90] |
| UCAI/CUDR | UCAI/CUDR is involved in chemotherapeutic resistance. | [91] |

Table 3: Continued.

| lncRNA | Potential role in HCC | Ref. |
|--------|-----------------------|------|
| PVT1   | High expression level of PVT1 is linked with tumor progression and may act as biomarker of tumor recurrence in HCC patients. IncRNA-p21 is downregulated in HCC and its overexpression inhibits tumor invasion by inhibiting Notch signaling and EMT. | [91] |
| IncRNA-p21 | Uregulation of UCAI is associated with progression of HCC via activation of FGFR1-ERK signaling pathway and inhibition of miR-216b. MT1DP acts as tumor suppressor and inhibits FOXA1 in liver cancer cells because of negative regulation of MT1DP by YAP and RUNx2. | [92] |
| UCAI   | Urapulation of HF1 promotes cell cycle progression and HCC cell proliferation. Downregulation of SRIC inhibits cancer proliferation; however, the epigenetically silenced SRIC promotes proliferation in HCC. | [93] |
| MT1DP  | PCNA-ASI is associated with reduction in HCC metastasis and invasion. IncRNA-Dreh is important in tumor suppression. Downregulation of Dreh inhibits HCC metastasis by targeting vimentin. | [94] |
| SRIC   | Urapulation of HF1 promotes cell cycle progression and HCC cell proliferation. Downregulation of SRIC inhibits cancer proliferation; however, the epigenetically silenced SRIC promotes proliferation in HCC. | [95] |
| PCNA-ASI | PCNA-ASI can serve as therapeutic target because it promotes tumor growth in HCC. | [96] |
| IncRNA-LET | Downregulation of LET is associated with reduction in HCC metastasis and invasion. IncRNA-Dreh is important in tumor suppression. Downregulation of Dreh inhibits HCC metastasis by targeting vimentin. | [97] |
| IncRNA-Dreh | Downregulation of Dreh inhibits HCC metastasis by targeting vimentin. | [98] |
| UCAI/CUDR | UCAI/CUDR is involved in chemotherapeutic resistance. | [99] |

(allyl mercaptan) [165]. Bioactive polyphenol resveratrol produced naturally in blueberries, grapes, and strawberries exhibited chemopreventive effects in liver cancer by promoting apoptosis [166]. In addition to this, resveratrol induced anticancer properties such as inflammation and attenuation of oxidative stress in hepatocarcinogenesis [167, 168]. Sodium butyrate produced as a result of metabolic degradation of carbohydrates in human colon and an isothiocyanate sulforaphane found in cruciferous vegetables prevent HCC by inhibiting HDACs [169, 170]. In a nutshell, nutritive epigenetics may serve as potential strategy to prevent HCC progression.

9. Epigenetic-Based Therapeutics for HCC and Future Updates

It is evident that epigenetic alterations play an important role in HCC and therefore can be targeted for treatment. In fact, in recent years the epigenetic drugs are in progress that reverse histone modification and methylation status. Combination of epigenetic drugs may also treat HCC (Table 4).
Table 4: Drugs that target epigenetic modifications in HCC [3].

| Epigenetic modification                                      | Drugs                        | Results                                                  | Ref.  |
|--------------------------------------------------------------|------------------------------|----------------------------------------------------------|-------|
| Histone deacetylation that targets histone deacetylase       | Suberoylanilide hydroxamic acid | TNF-related apoptosis-inducing ligand-induced apoptosis. | [100] |
| Belinostat                                                   | Tumor stabilization was observed in nonresectable advanced HCC. | [101] |
| Belinostat                                                   | Induction of apoptosis and inhibition of cell growth occurred. | [102] |
| DNA methylation that targets DNA methyltransferases          | 5-Aza-2′-deoxycytidine       | Inhibition of telomerase activity and reactivation of c-Myc and p16 were observed. | [103] |
| Zebularine                                                   | Induction of apoptosis and inhibition of cell proliferation were observed in HepG2 cell line. | [104] |
| Zebularine                                                   | Tumor growth was inhibited in xenograft models. Genes involved in apoptosis, cell cycle, and tumor suppression were demethylated in KMHC and Huh-7 cell lines. | [105] |
| Combined epigenetic modifications that target tyrosine kinase inhibitors and histone deacetylase inhibitors | Panobinostat + sorafenib     | Combined activity of these two drugs induced apoptosis, increased survival, and decreased tumor density and tumor volume. | [106] |

HCC patients can be treated with HDAC inhibitors such as valproic acid, TSA, panobinostat, ITF2357, resminostat, givinostat, abexinostat, CUDC-101, and pracinostat that have given encouraging results in HCC patients because aberrant expression of HDAC is higher in cancer patients [101, 106, 171–174]. Epigenetic drugs can stimulate the immunity of host by increasing tumor antigen presentation [175].

MiRNAs with tumor-suppressor nature are perfect anti-cancer agents because of their ability to modulate multiple signaling pathways in cancer growth. Modulation of expression of miRNAs or targeting any tumor-related deregulated ncRNA may offer potential new therapeutic strategies.

Histone-modifying enzymes and DNMTs are the prime candidates for future HCC therapy. Series of clinical studies are currently under research for the development of epigenetic-based therapies to combat life-threatening condition HCC.

10. Conclusion

The above studies provide strong evidence that epigenetic alterations are in close association with disease stage and clinical outcome in HCC. The best-known genetic abnormalities in HCC are dysregulated expression of epigenetic regulatory genes, aberrant expression of noncoding RNAs, promoter methylation, and DNA methylation. Several different epidrugs target these aberrations and control the progression of HCC by reversing the expression of cell cycle and apoptosis related genes. Epigenetic alterations can potentially be considered an alternative option in cancer treatment protocols because epigenetic changes are reversible unlike genetic changes that are irreversible. Epigenetic changes affect cellular transcriptome alterations and result in gene expression and chromatin organization more extensively than genetic changes. Many of drugs with the potential to change the pattern or level of histone modification and DNA methylation have been developed and are now in clinical trials. As prognostic and diagnostic biomarker of HCC, it has been shown that histone modification, DNA methylation, and differential expression of noncoding RNAs help researchers to distinguish between HCC and cirrhotic liver or between tumor and nontumor adjacent tissues. Multikinase inhibitor, Sorafenib, is the first drug that treats HCC. HCC can be suppressed by inhibition of expression or activity of key proteins involved in carcinogenesis; therefore, epigenetic modulation of histones and the expression regulation of miRNAs serve as useful therapeutic strategies against HCC. Detailed mechanisms of HCC-related epigenetic-based therapeutics remain to be explored. Last but not least, targeted and efficient use of epigenetic drugs makes them prime candidates for future HCC therapy.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.

[2] Z. Herceg and A. Paliwal, “Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome,” Mutation Research/Reviews in Mutation Research, vol. 727, no. 3, pp. 55–61, 2011.
[3] L. Ma, M.-S. Chua, O. Andrisani, and S. So, "Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives," *World Journal of Gastroenterology*, vol. 20, no. 2, pp. 333–345, 2014.

[4] Y. Zhang, "Detection of epigenetic aberrations in the development of hepatocellular carcinoma," in *Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis*, pp. 709–731, Springer, 2015.

[5] L. Revill, T. Wang, A. Lachenmayer et al., "Genome-wide DNA methylation analysis of multiple CpG islands in gastric cancers," *Oncotarget*, vol. 8, no. 51, pp. 741–751, 2016.

[6] T. Etoh, Y. Kanai, S. Ushijima et al., "Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation in multiple CpG islands in gastric cancers," *The American Journal of Pathology*, vol. 164, no. 2, pp. 689–699, 2004.

[7] K. Liu, Y. Zhang, C. Zhang et al., "Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma," *Oncotarget*, vol. 7, no. 35, pp. 56798–56810, 2016.

[8] I. Hernando-Herraez, R. Garcia-Perez, A. J. Sharp, and T. Marques-Bonet, "DNA methylation: insights into human evolution," *PLoS Genetics*, vol. 11, no. 12, Article ID e1005661, 2015.

[9] E. L. Sceusi, D. S. Loose, and C. J. Wray, "Clinical implications of DNA methylation in hepatocellular carcinoma," *HBP*, vol. 13, no. 6, pp. 369–376, 2011.

[10] M. Weber, I. Hellmann, M. B. Stadler et al., "Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome," *Nature Genetics*, vol. 39, no. 4, pp. 457–466, 2007.

[11] M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman, "A gene hypermethylation profile of human cancer," *Cancer Research*, vol. 61, no. 8, pp. 3225–3229, 2001.

[12] Y. F. He, B.-Z. Li, Z. Li et al., "Tet-mediated formation of 5-carboxycytosine and its excision by TDG in mammalian DNA," *Science*, vol. 333, no. 6047, pp. 1303–1307, 2011.

[13] M. C. Haffner, A. Chaux, A. K. Meeker et al., "Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers," *Oncotarget*, vol. 2, no. 8, pp. 627–637, 2013.

[14] S.-G. Jin, Y. Jiang, R. Qiu et al., "5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDHI mutations," *Cancer Research*, vol. 71, no. 24, pp. 7360–7365, 2011.

[15] M.-A. Song, M. Türikainen, S. Kwee, G. Okimoto, H. Yu, and L. L. Wong, "Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma," *PLoS ONE*, vol. 8, no. 2, Article ID e55761, 2013.

[16] M.-P. Lambert, P.-B. Ancey, D. D. Esposti et al., "Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors," *Clinical Epigenetics*, vol. 7, no. 1, p. 1, 2015.

[17] T. Etoh, Y. Kanai, S. Ushijima et al., "Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation in multiple CpG islands in gastric cancers," *The American Journal of Pathology*, vol. 164, no. 2, pp. 689–699, 2004.

[18] K. Liu, Y. Zhang, C. Zhang et al., "Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma," *Oncotarget*, vol. 7, no. 35, pp. 56798–56810, 2016.

[19] H. G. Lee, H. Kim, T. Son et al., "Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma," *Oncotarget*, vol. 7, no. 27, pp. 41798–41810, 2016.

[20] W.-R. Liu, Y.-H. Shi, Y.-F. Peng, and J. Fan, "Epigenetics of hepatocellular carcinoma: a new horizon," *Chinese Medical Journal*, vol. 125, no. 13, pp. 2349–2360, 2012.

[21] N. Nishida and A. Goe, "Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review," *Current Genomics*, vol. 12, no. 2, pp. 130–137, 2011.

[22] S. B. Baylin, "DNA methylation and gene silencing in cancer," *Nature Clinical Practice Oncology*, vol. 2, no. 1, pp. S4–S11, 2005.

[23] Z. Herceg, "Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors," *Mutagenesis*, vol. 22, no. 2, pp. 91–103, 2007.

[24] C. Sawan, T. Vaissière, R. Murr, and Z. Herceg, "Epigenetic drivers and genetic passengers on the road to cancer," *Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 642, no. 1-2, pp. 1–13, 2008.

[25] M.-P. Lambert, A. Paliwal, T. Vaissière et al., "Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake," *Journal of Hepatology*, vol. 54, no. 4, pp. 705–715, 2011.

[26] F. H.-T. Duong, V. Christen, S. Lin, and M. H. Heim, "Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair," *Hepatology*, vol. 51, no. 3, pp. 741–751, 2010.

[27] M. R. Higgs, H. Lerat, and J.-M. Pawlotsky, "Downregulation of Gadd45β expression by hepatitis C virus leads to defective cell cycle arrest," *Cancer Research*, vol. 70, no. 12, pp. 4901–4911, 2010.

[28] H. Hernandez-Vargas, M.-P. Lambert, F. Le Calvez-Kelm et al., "Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors," *PLoS ONE*, vol. 5, no. 3, Article ID e9749, 2010.

[29] C. Ye, R. Tao, Q. Cao et al., "Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma," *Age (Years)*, vol. 41, no. 53, pp. 40, 2016.

[30] X. Tang, L. Ge, Z. Chen et al., "Methylation of the constitutive androstane receptor is involved in the suppression of CYP2C19 in hepatitis B Virus-associated hepatocellular carcinoma," *Drug Metabolism and Disposition*, vol. 44, no. 10, pp. 1643–1652, 2016.

[31] Y.-L. Shih, C.-C. Kuo, M.-D. Yan, Y.-W. Lin, C.-B. Hsieh, and T.-Y. Hsieh, "Quantitative methylation analysis reveals distinct association between PAX6 methylation and clinical characteristics with different viral infections in hepatocellular carcinoma," *Clinical Epigenetics*, vol. 8, no. 1, article 41, 2016.

[32] J. Shen, S. Wang, Y.-J. Zhang et al., "Genome-wide DNA methylation profiles in hepatocellular carcinoma," *Hepatology*, vol. 55, no. 6, pp. 1799–1808, 2012.

[33] N. Nishida, M. Kudo, T. Nagasaka, I. Ikai, and A. Goel, "Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma," *Hepatology*, vol. 56, no. 3, pp. 994–1003, 2012.

[34] K. Revill, T. Wang, A. Lachenmayer et al., "Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma," *Gastroenterology*, vol. 145, no. 6, pp. 1424.e25–1435.e25, 2013.

[35] J. Bielawska, T. Kozłowski, T. J. van de Poll-Franse, and E. J. Overveld, "DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma," *World Journal of Gastroenterology*, vol. 20, no. 24, pp. 7894–7913, 2014.

[36] H. Liu, H. Dong, K. Robertson, and C. Liu, "DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma," *The American Journal of Pathology*, vol. 178, no. 2, pp. 652–661, 2011.

[37] I. Tischler, A. Markworth, H. Witzigmann et al., "Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors," *International Journal of Cancer*, vol. 115, no. 5, pp. 684–689, 2005.
C. Zhang, X. Guo, G. Jiang et al., “CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma,” International Journal of Cancer, vol. 123, no. 5, pp. 998–1004, 2008.

M. L. Tomasi, T. W. H. Li, M. Li, J. M. Mato, and S. C. Lu, “Inhibition of human methionine adenosyltransferase 1A transcription by coding region methylation,” Journal of Cellular Physiology, vol. 227, no. 4, pp. 1583–1591, 2012.

O. Warburg, F. Wind, and F. Neglers, “The metabolism of tumours,” in Metabolism of Tumours, pp. 254–270, Constable & Co, London, UK, 1930.

K. Cao, J. Li, Y. Zhao et al., “miR-101 inhibiting cell proliferation, migration and invasion in hepatocellular carcinoma through downregulating girdin,” Molecules and Cells, vol. 39, no. 2, pp. 96–102, 2016.

T. Ruan, X. He, J. Yu, and Z. Hang, “MicroRNA-186 targets yes-associated protein 1 to inhibit hippo signaling and tumorigenesis in hepatocellular carcinoma,” Oncology Letters, vol. 11, no. 4, pp. 2941–2945, 2016.

S. Parpart, S. Roessler, F. Dong et al., “Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome,” Hepatology, vol. 60, no. 3, pp. 872–883, 2014.

L. Zhao and W. Wang, “miR-125b suppresses the proliferation of hepatocellular carcinoma cells by targeting Sirtuin1,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 10, pp. 18469–18475, 2015.

Z. Liu, C. Dou, B. Yao et al., “Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma,” Oncotarget, vol. 7, no. 24, pp. 36909–36923, 2016.

M. Kelong, Y. He, H. Zhang et al., “DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression,” Journal of Biological Chemistry, vol. 287, no. 8, pp. 5639–5649, 2012.

Z. Tian, H. Jiang, Y. Liu et al., “MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1,” Experimental Cell Research, vol. 343, no. 2, pp. 135–147, 2016.

Z. Luo, C. Feng, P. Hu et al., “Serum microRNA-199a/b-3p as a predictive biomarker for treatment response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization,” Oncotargets and Therapy, vol. 9, pp. 2667–2674, 2016.

Q. Shen, V. R. Cinccinati, X. Zhang et al., “Role of microRNA-199a-3p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion,” Molecular Cancer, vol. 9, no. 1, article 227, 2010.

B. Tang, B. Lei, G. Qi et al., “MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression,” Journal of Experimental and Clinical Cancer Research, vol. 35, no. 1, article 93, 2016.

Y.-F. Yang, F. Wang, J.-J. Xiao et al., “MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27,” International Journal of Clinical and Experimental Medicine, vol. 7, no. 4, pp. 893–902, 2014.

G. Xu, Y. Zhang, J. Wei et al., “MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase kinase 3,” BMC Cancer, vol. 13, no. 1, article 469, 2013.

S. Liu, K. Liu, W. Zhang et al., “MiR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma,” American Journal of Translational Research, vol. 8, no. 6, pp. 2609–2619, 2016.

C. C.-L. Wong, C. Wong, E. K. Tang et al., “The microRNA miR-133 promotes metastasis and progression of hepatocellular carcinoma by down-regulating rho-kinase 2,” Gastroenterology, vol. 140, no. 1, pp. 322–331, 2011.

Q. Bi, S. Tang, L. Xia et al., “Ectopic expression of miR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF,” PLoS ONE, vol. 7, no. 6, Article ID e40169, 2012.

G. Tan, L. Wu, J. Tan et al., “MiR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF-κB signaling pathway,” Scientific Reports, vol. 6, article 22328, 2016.

L. Zhang, F. Yang, J.-H. Yuan et al., “Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma,” Carcinogenesis, vol. 34, no. 3, pp. 577–586, 2013.

H. Tu, G. Wei, Q. Cai et al., “MicroRNA-212 inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting FOXA1,” Oncotargets and Therapy, vol. 8, pp. 2227–2235, 2015.

C. Dou, Y. Wang, C. Li et al., “MicroRNA-212 inhibits tumor growth of human hepatocellular carcinoma by targeting FOXA1,” Oncotarget, vol. 6, no. 15, pp. 13216–13228, 2015.

L. Zhang, Z. Yu, X. Xian, and X. Lin, “microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma,” FEBS Open Bio, vol. 6, no. 2, pp. 155–164, 2016.
Y. Li, W. Tan, T. W. L. Neo et al., “Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma,” Cancer Science, vol. 100, no. 7, pp. 1234–1242, 2009.

L. Yang, X. Zhang, H. Li, and J. Liu, “The long noncoding RNA HOTAIR activates autophagy by upregulating ATG3 and ATG7 in hepatocellular carcinoma,” Molecular BioSystems, vol. 12, no. 8, pp. 2605–2612, 2016.

J.-Z. Gao, J. Li, J.-L. Du, and X.-L. Li, “Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence,” Oncology Letters, vol. 11, no. 3, pp. 1791–1798, 2016.

L. Deng, S.-B. Yang, F.-F. Xu, and J.-H. Zhang, “Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge,” Journal of Experimental and Clinical Cancer Research, vol. 34, no. 1, article 18, 2015.

S. Li, H. Xu, Y. Yu et al., “LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway,” Oncotarget, vol. 7, no. 27, pp. 42431–42446, 2016.

J. Wu, Y. Qin, B. Li, W.-Z. He, and Z.-L. Sun, “Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGf2 and H19 in human hepatocellular carcinoma,” Genomics, vol. 91, no. 5, pp. 443–450, 2008.

L. Quagliata, M. S. Matter, S. Piscuoglio et al., “Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients,” Hepatology, vol. 59, no. 3, pp. 911–923, 2014.

F. H. C. Tsang, S. L. K. Au, L. Wei et al., “Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b,” Liver International, vol. 35, no. 5, pp. 1597–1606, 2015.

T. Zhou and Y. Gao, “Increased expression of LncRNA BANCRI and its prognostic significance in human hepatocellular carcinoma,” World Journal of Surgical Oncology, vol. 14, no. 1, article 8, 2016.

M.-C. Lai, Z. Yang, L. Zhou et al., “Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation,” Medical Oncology, vol. 29, no. 3, pp. 1810–1816, 2012.

F. Yang, L. Zhang, X.-S. Huo et al., “Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans,” Hepatology, vol. 54, no. 5, pp. 1679–1689, 2011.

C.-L. Chen, Y.-W. Tseng, J.-C. Wu et al., “Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation,” Biomaterials, vol. 44, pp. 71–81, 2015.

D. Zhang, C. Cao, L. Liu, and D. Wu, “Up-regulation of LncRNA SNHG20 predicts poor prognosis in hepatocellular carcinoma,” Journal of Cancer, vol. 7, no. 5, pp. 608–617, 2016.

H. Zhuo, J. Tang, Z. Lin et al., “The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma,” Molecular Carcinogenesis, vol. 55, no. 2, pp. 209–219, 2016.

T. Kogure, I. K. Yan, W.-L. Lin, and T. Patel, “Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer,” Genes and Cancer, vol. 4, no. 7-8, pp. 261–272, 2013.

C. Braconi, N. Valeri, T. Kogure et al., “Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 2, pp. 786–791, 2011.

K. Takahashi, I. K. Yan, H. Haga, and T. Patel, “Modulation of hypoxia-signaling pathways by extracellular linc-RoR,” Journal of Cell Science, vol. 127, no. 7, pp. 1585–1594, 2014.

J. Z. Gao, J. Li, J.-L. Du, and X.-L. Li, “Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence,” Oncology Letters, vol. 11, no. 3, pp. 1791–1798, 2016.

L. Deng, S.-B. Yang, F.-F. Xu, and J.-H. Zhang, “Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge,” Journal of Experimental and Clinical Cancer Research, vol. 34, no. 1, article 18, 2015.

S. Li, H. Xu, Y. Yu et al., “LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway,” Oncotarget, vol. 7, no. 27, pp. 42431–42446, 2016.

J. Wu, Y. Qin, B. Li, W.-Z. He, and Z.-L. Sun, “Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGf2 and H19 in human hepatocellular carcinoma,” Genomics, vol. 91, no. 5, pp. 443–450, 2008.

L. Quagliata, M. S. Matter, S. Piscuoglio et al., “Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients,” Hepatology, vol. 59, no. 3, pp. 911–923, 2014.

F. H. C. Tsang, S. L. K. Au, L. Wei et al., “Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b,” Liver International, vol. 35, no. 5, pp. 1597–1606, 2015.
carcinoma,” *Journal of Cancer Research and Clinical Oncology*, vol. 141, no. 7, pp. 1195–1203, 2014.

[97] S.-X. Yuan, Q.-F. Tao, J. Wang et al., “Antisense long non-coding RNA PCNA-ASI promotes tumor growth by regulating proliferating cell nuclear antigen in hepatocellular carcinoma,” *Cancer Letters*, vol. 349, no. 1, pp. 87–94, 2014.

[98] J.-F. Huang, Y.-J. Guo, C.-X. Zhao et al., “Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin,” *Hepatology*, vol. 57, no. 5, pp. 1882–1892, 2013.

[99] W. P. Tsang, T. W. L. Wong, A. H. H. Cheung, C. N. N. Co, and T. T. Kwok, “Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR,” *RNA*, vol. 13, no. 6, pp. 890–898, 2007.

[100] D. Carlisi, M. Lauricella, A. D’Anneo et al., “The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL–DISC activation,” *European Journal of Cancer*, vol. 45, no. 13, pp. 2425–2438, 2009.

[101] W. Yeo, H. C. Chung, S. L. Chan et al., “Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the mayo phase II consortium and the cancer therapeutics research group,” *Journal of Clinical Oncology*, vol. 30, no. 27, pp. 3361–3367, 2012.

[102] B. B. Y. Ma, F. Sung, Q. Tao et al., “The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines,” *Investigational New Drugs*, vol. 28, no. 2, pp. 107–114, 2010.

[103] S.-F. Tao, C.-S. Zhang, X.-L. Guo et al., “Anti-tumor effect of 5-aza-2′-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells,” *World Journal of Gastroenterology*, vol. 18, no. 19, pp. 2334–2343, 2012.

[104] K. Nakamura, K. Aizawa, K. Nakabayashi et al., “DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis,” *PLoS ONE*, vol. 8, no. 1, Article ID e54036, 2013.

[105] J. B. Andersen, V. M. Factor, J. U. Marquardt et al., “An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer,” *Science Translational Medicine*, vol. 2, no. 54, p. 54ra77, 2010.

[106] A. Lachenmayer, S. Toffanin, L. Cabellos et al., “Combination group protein EZH2 is involved in progression of prostate cancer,” *Nature*, vol. 419, no. 6907, pp. 624–629, 2002.

[107] S. Bhattacharya, D. Reddy, A. Ingle, B. Khade, and S. Gupta, “Brief Communication: Featured Article: Histone H2A mono-ubiquitination and cellular transformation are inversely related in N-nitrosodiethylamine-induced hepatocellular carcinoma,” *Experimental Biology and Medicine* (Maywood, N.J.), vol. 241, no. 16, pp. 1739–1744, 2016.

[108] C. Magerl, J. Ellinger, T. Braunschweig et al., “H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1,” *Human Pathology*, vol. 41, no. 2, pp. 181–189, 2010.

[109] J. K. Shon, B. H. Shon, I. Y. Park et al., “Hepatitis B virus-X protein recruits histone deacetylase I to repress insulin-like growth factor binding protein 3 transcription,” *Virus Research*, vol. 139, no. 1, pp. 14–21, 2009.

[110] K. Schulze, S. Imbeaud, E. Letouzé et al., “Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets,” *Nature Genetics*, vol. 47, no. 5, pp. 505–511, 2015.

[111] W.-K. Sung, H. Zheng, S. Li et al., “Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma,” *Nature Genetics*, vol. 44, no. 7, pp. 765–769, 2012.

[112] C. He, J. Xu, J. Zhang et al., “High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma,” *Human Pathology*, vol. 43, no. 9, pp. 1425–1435, 2012.

[113] C. M. Wong, L. Wei, C. T. Law et al., “Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis,” *Hepatology*, vol. 63, no. 2, pp. 474–487, 2016.

[114] X. Zhang, J. Wu, J. Choiniere et al., “Arsenic silences hepatic PDK4 expression through activation of histone H3K9 methyltransferase G9a,” *Toxicology and Applied Pharmacology*, vol. 304, pp. 42–47, 2016.

[115] T. Longerich, “Dysregulation of the epigenetic regulator SETDB1 in liver carcinogenesis—more than one way to skin a cat,” *Chinese Clinical Oncology*, vol. 5, no. 6, pp. 72–72, 2016.

[116] J. Zhu, “DNA methylation and hepatocellular carcinoma,” *Journal of Hepato-Biliary-Pancreatic Surgery*, vol. 13, no. 4, pp. 265–273, 2006.

[117] Y.-J. Liao, S.-P. Liu, C.-M. Lee et al., “Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: implications of the gender disparity in liver cancer susceptibility,” *International Journal of Cancer*, vol. 124, no. 4, pp. 816–826, 2009.

[118] A. Moeini, H. Cornella, and A. Villanueva, “Emerging signaling pathways in hepatocellular carcinoma,” *Liver Cancer*, vol. 1, no. 2, pp. 83–93, 2012.
B. G. Wilson and C. W. M. Roberts, "SWI/SNF nucleosome remodelers and cancer," Nature Reviews Cancer, vol. 11, no. 7, pp. 481–492, 2011.

M. Endo, K. Yasui, Y. Zen et al., "Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma," Liver International, vol. 33, no. 1, pp. 105–117, 2013.

C. Guichard, G. Amaddeo, S. Imbeaud et al., "Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma," Nature Genetics, vol. 44, no. 6, pp. 694–698, 2012.

M. Li, H. Zhao, X. Zhang et al., "Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma," Nature Genetics, vol. 43, no. 9, pp. 828–829, 2011.

M. Liu, L. Chen, N.-F. Ma et al., "CHDIL promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors," Hepatology, vol. 63, no. 5, pp. 1544–1559, 2016.

Z. Wang and X. Li, "The role of noncoding RNA in hepatocellular carcinoma," Gland Surgery, vol. 2, no. 1, p. 25, 2013.

J. George and T. Patel, "Noncoding RNA as therapeutic targets for hepatocellular carcinoma," in Seminars in Liver Disease, Thieme Medical Publishers, Stuttgart, Germany, 2015.

Z. Liu, J. Wang, Y. Mao, B. Zou, and X. Fan, "MicroRNA-101 suppresses migration and invasion via targeting vascular endothelial growth factor-C in hepatocellular carcinoma cells," Oncology Letters, vol. 11, no. 1, pp. 433–438, 2016.

Z. Najafi, M. Sharifi, and G. Javadi, "Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma," Cancer Gene Therapy, vol. 22, no. 11, pp. 530–535, 2015.

P. Wang, S. Chen, H. Fang et al., "miR-214/199a/199a∗ cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators," Oncotarget, vol. 7, no. 1, pp. 929–945, 2016.

X. Q. Jia, H. Q. Cheng, X. Qian et al., "Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma," Cell Biochemistry and Biophysics, vol. 62, no. 1, pp. 237–244, 2012.

S. Zhu, C. M. Chen, Z. Y. Jiang et al., "MicroRNA-185 inhibits cell proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Six2," European Review for Medical and Pharmacological Sciences, vol. 20, no. 9, pp. 1712–1719, 2016.

Z. Hou, H.-Q. Zhu, C.-Q. Ma et al., "miR-1180 promotes the proliferation of hepatocellular carcinoma cells by repressing TNIP2 expression," Biomedicine & Pharmacotherapy, vol. 79, pp. 315–320, 2016.

Y.-B. Zeng, X.-H. Liang, G.-X. Zhang et al., "miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1," Cancer Cell International, vol. 16, no. 1, article 63, 2016.

Y. He, X.-M. Meng, C. Huang et al., "Long noncoding RNAs: novel insights into hepatocellular carcinoma," Cancer Letters, vol. 344, no. 1, pp. 20–27, 2014.

Y. Gao, G. Chen, Y. Zeng et al., "Invasion and metastasis-related long noncoding RNA expression profiles in hepatocellular carcinoma," Tumor Biology, vol. 36, no. 10, pp. 7409–7422, 2015.

D. Ngo-Yin Fan, F. Ho-Ching Tsang, A. Hoi-Kam Tam et al., "Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b," Hepatology, vol. 57, no. 2, pp. 637–647, 2013.

W. Mah and C. G. Lee, "DNA methylation: potential biomarker in Hepatocellular Carcinoma," Biomarker Research, vol. 2, no. 1, article 5, 2014.

K. Kojima, A. Takata, C. Vadanis et al., "MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma," Nature Communications, vol. 2, article 338, 2011.

J. Hou, L. Lin, W. Zhou et al., "Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma," Cancer Cell, vol. 19, no. 2, pp. 232–243, 2011.
[160] R. Nagashio, E. Arai, H. Ojima, T. Kosuge, Y. Kondo, and Y. Kanai, “Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage,” International Journal of Cancer, vol. 129, no. 5, pp. 1170–1179, 2011.

[161] M.-H. Teiten, M. Dicato, and M. Diederich, “Curcumin as a regulator of epigenetic events,” Molecular Nutrition and Food Research, vol. 57, no. 9, pp. 1619–1629, 2013.

[162] A. S. Darvesh and A. Bishayee, “Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer,” Nutrition and Cancer, vol. 65, no. 3, pp. 329–344, 2013.

[163] W. J. Lee and B. T. Zhu, “Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols,” Carcinogenesis, vol. 27, no. 2, pp. 269–277, 2006.

[164] K. S. Furtado, J. Polletini, M. C. Dias, M. A. M. Rodrigues, and L. F. Barbisan, “Prevention of rat liver fibrosis and carcinogenesis by coffee and caffeine,” Food and Chemical Toxicology, vol. 64, pp. 20–26, 2014.

[165] C. Verslype, “Interfering with epigenetics in hepatocellular carcinoma: out of the shelter?” Journal of Hepatology, vol. 65, no. 2, pp. 243–244, 2016.

[166] A. Bishayee and N. Dhir, “Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis,” Chemico-Biological Interactions, vol. 179, no. 2-3, pp. 131–144, 2009.

[167] A. Bishayee, A. Waghray, K. F. Barnes et al., “Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis,” Pharmaceutical Research, vol. 27, no. 6, pp. 1080–1091, 2010.

[168] A. Bishayee, T. Politis, and A. S. Darvesh, “Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma,” Cancer Treatment Reviews, vol. 36, no. 1, pp. 43–53, 2010.

[169] H.-G. Wang, X.-D. Huang, P. Shen, L.-R. Li, H.-T. Xue, and G.-Z. Li, “Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro,” International Journal of Molecular Medicine, vol. 31, no. 4, pp. 967–974, 2013.

[170] J. D. Clarke, R. H. Dashwood, and E. Ho, “Multi-targeted prevention of cancer by sulforaphane,” Cancer Letters, vol. 269, no. 2, pp. 291–304, 2008.

[171] M. Mottamal, S. Zheng, T. L. Huang, and G. Wang, “Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents,” Molecules, vol. 20, no. 3, pp. 3898–3941, 2015.

[172] R. Buurman, E. Girlevik, V. Schiffer et al., “Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells,” Gastroenterology, vol. 145, no. 3, pp. 811–820.e15, 2012.

[173] S. Armeanu, A. Pathil, S. Venturelli et al., “Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357,” Journal of Hepatology, vol. 42, no. 2, pp. 210–217, 2005.

[174] A. Pathil, S. Armeanu, S. Venturelli et al., “HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL,” Hepatology, vol. 43, no. 3, pp. 425–434, 2006.

[175] Z. S. Guo, J. A. Hong, K. R. Irvine et al., “De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model,” Cancer Research, vol. 66, no. 2, pp. 1105–1113, 2006.